Benchmark Maintains Speculative Buy on Harvard Bioscience, Lowers Price Target to $0.6
Benzinga Newsdesk 7 months ago
NewsPrice TargetAnalyst Ratings
Benchmark analyst Bruce D. Jackson maintains Harvard Bioscience (NASDAQ:HBIO) with a Speculative Buy and lowers the price target from $2 to $0.6.
Benchmark analyst Bruce D. Jackson maintains Harvard Bioscience (NASDAQ:HBIO) with a Speculative Buy and lowers the price target from $2 to $0.6.